NAD+: IV Kinetics, NR/NMN Precursors, and Dose References

Quick Reference Card

This schematic separates normal NAD metabolism from the evidence for administered NAD+, NR and NMN. The cardiac trial and preliminary injection reports address specific products and settings, not general rejuvenation [1][3][14][15][16].

What NAD+ is

NAD+ is a nucleotide coenzyme central to redox reactions, mitochondrial metabolism, DNA repair signaling, sirtuin activity, and PARP activity. It is not a peptide and it is not interchangeable with peptide hormones or growth-factor fragments [1].

The NAD marketplace often compresses three different categories into one story: direct NAD+ administration, oral precursor supplementation, and anti-aging claims. The evidence is clearer when those categories remain separate.

Direct IV NAD+ evidence

The best-known direct IV NAD+ human study is a pilot that infused 750 mg NAD+ over 6 hours in men and measured changes in plasma and urine metabolites [1]. Plasma NAD+ and metabolites did not show major changes early in the infusion, while urinary NAD+ and methylated metabolites increased later. The authors interpreted the pattern as rapid metabolism and clearance rather than straightforward durable plasma NAD+ loading [1].

That study is useful because it describes human kinetics under a defined IV condition. It does not test longevity, cognition, addiction recovery, fatigue, athletic performance, or mitochondrial rejuvenation outcomes.

NCT06382688 has no results posted in its registry, which has unknown status after its last update in April 2024 [2]. However, a linked June 2024 preprint reports the comparison of 500 mg IV NAD+, IV NR, oral NR, and placebo [14]. The authors reported shorter infusions and better tolerability with IV NR. This ChromaDex-funded pilot has not been peer reviewed and did not demonstrate anti-aging benefit.

An April 2026 preprint adds a 45-person pilot of 100 mg NAD+ or NR by IV, IM, or SC administration over three days. Its second trial extended NR administration, not NAD+, in 39 participants [15]. These descriptive safety findings do not establish the effectiveness of commercial protocols.

A trial published online in September 2025 and in the January 2026 journal issue studied 180 patients with ischemic heart failure. Adding 10 mg/day IV NAD+ for seven days to usual treatment improved ejection fraction at one month. The six-month composite cardiovascular event endpoint did not differ significantly (p = 0.089) [16]. This single-center study provides disease-specific evidence; it does not validate 250–1,000 mg wellness doses.

NR and NMN are precursor evidence, not NAD+ evidence

NR and NMN can raise NAD-related metabolites, but they are not the same administered compound as NAD+. The Trammell study tested oral nicotinamide riboside chloride at 100 mg, 300 mg, and 1,000 mg single doses in healthy adults and showed dose-related changes in the NAD metabolome [3][4].

NMN studies use different products and schedules. NCT04823260 and the associated publication evaluated 300 mg/day, 600 mg/day, and 900 mg/day for 60 days [5][6]. Pencina and colleagues studied MIB-626, a microcrystalline beta-NMN product, at 1,000 mg twice daily for 28 days in overweight or obese adults [7].

These studies support NAD-precursor biology. They do not prove that direct IV or SC NAD+ clinic protocols produce the same exposure, outcomes, or safety profile.

Regulatory and claims context

FDA dietary-supplement information emphasizes that supplements are regulated differently from drugs and are not preapproved for safety and effectiveness before marketing [9]. FDA’s submitted-NDI page listed NMN-related notifications in 2026, reflecting an evolving supplement-status record [8]. Those records do not create an FDA-approved drug indication for anti-aging, mitochondrial enhancement, addiction treatment, or cognitive enhancement.

For NAD+ itself, this refresh did not identify an FDA-approved NAD+ injectable label for wellness or anti-aging use. Public IV pages and compound guides therefore sit in a different evidence category from approved drug labeling.

Where the evidence conflicts

Direct evidence includes the 750 mg IV kinetics pilot, a 10 mg/day cardiac trial, and preliminary safety reports [1][14][15][16]. The strongest oral evidence often comes from NR and NMN precursor trials [3][4][5][6][7]. Public NAD+ clinic pages list 250-1,000 mg IV sessions, SC ranges, loading cycles, and maintenance concepts [10][11][12][13].

Those categories answer different questions. Direct IV NAD+ data describe rapid metabolism and urinary metabolite changes. Precursor trials describe oral bioavailability and NAD-related metabolite changes. Clinic pages describe commercial practice patterns. A single consensus dose would erase that difference.

Safety and tolerability details worth preserving

The direct IV pilot was small and not designed to define rare safety risks [1]. Public IV clinic pages commonly discuss infusion tolerance, including nausea, flushing, headache, abdominal discomfort, fatigue, muscle tension, and chest tightness when infusion speed is poorly tolerated [11]. These symptoms are practice-page claims, but they are still useful logging fields because IV NAD+ is often marketed as a long infusion.

Supplement-status questions are separate from tolerability. NR and NMN oral trials cannot be used as safety substitutes for compounded IV NAD+ products, because product quality, sterile handling, dose timing, and route differ.

What Doserly helps track

Doserly NAD-related records work best when the entry name is specific: NAD+, NR, NMN, reduced NADH, or a branded precursor product. Useful fields include route, dose, infusion duration, product identity, vendor or clinic source, co-administered compounds, adverse effects during infusion, labs, sleep or energy scales, and the cited source row used for comparison.

Academy discussions can separate direct NAD+ kinetics from NR/NMN precursor studies and from public clinic dose menus, which makes contradictions easier to evaluate.

FAQ

Is NAD+ a peptide?

No. NAD+ is a nucleotide coenzyme. It belongs in a redox and metabolism category rather than a peptide-signaling category [1].

Does the 750 mg IV pilot prove anti-aging benefit?

No. The 750 mg infusion study measured plasma and urine NAD-related metabolites during a 6-hour infusion. It did not test lifespan, biological age, frailty, cognition, or symptom outcomes [1].

Can NR or NMN trial doses be used as NAD+ doses?

No. NR and NMN are precursors with their own pharmacology and product-specific data [3][4][5][6][7]. Their oral trial doses provide context for NAD biology, not direct IV NAD+ dosing proof.

What makes the public NAD+ dose pages useful?

They document what clinics and community pages publish: IV 250-1,000 mg sessions, SC ranges, and maintenance concepts [10][11][12][13]. The guide treats those rows as public claims because they are not equivalent to controlled outcome trials.

Did the refresh find FDA-approved NAD+ anti-aging labeling?

No approved anti-aging or wellness NAD+ label was identified. FDA supplement resources and NDI listings are regulatory-context sources, not approvals for anti-aging use [8][9].

References

[1] Grant R. et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+.

[2] ClinicalTrials.gov: IV Administration of ChromaDex’s Niagen as Compared to NAD+, NCT06382688.

[3] Trammell S.A.J. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.

[4] ClinicalTrials.gov: Nicotinamide Riboside Pharmacokinetics, NCT02191462.

[5] ClinicalTrials.gov: Assessment of the Efficacy and Safety of Uthever in Middle Aged and Older Adults, NCT04823260.

[6] Yi L. et al. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults.

[7] Pencina K.M. et al. MIB-626 increases blood NAD levels in middle-aged and older adults.

[8] FDA: Submitted 75-day premarket notifications for new dietary ingredients.

[9] FDA: Questions and Answers on Dietary Supplements.

[10] PeptideWiki: NAD+ dosage guide.

[11] AZ IV Medics: NAD IV dose guide.

[12] FormBlends: Longevity dosage guide including NAD+.

[13] Biomogging: NAD+ compound page.

[14] Hawkins et al. Randomized, placebo-controlled pilot study evaluating acute Niagen+ IV and NAD+ IV (2024; preprint).

[15] Nkrumah-Elie et al. Preliminary Safety Analysis of Two Pilot Clinical Trials Involving Injections of Niagen (2026; preprint).

[16] Yu et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.